SCHEMBL433705

SCHEMBL433705

N#Cc1cc2c(cc1N)CCC2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PGR P06401 2/20 0.38
PBRM1 Q86U86 1/20 0.38
GRM5 P41594 1/20 0.36
HSD17B1 P14061 2/20 0.34
NPSR1 Q6W5P4 3/20 0.33
KDM4E B2RXH2 3/20 0.33
USP8 P40818 1/20 0.33
USP7 Q93009 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
EGFR P00533 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518973 0.79 PGR (0.38) CASP1CASP7HSD17B10PGRPBRM1
SCHEMBL460543 0.78 CASP1 (0.57) CASP1CASP7HSD17B10PBRM1GRM5
SCHEMBL23792337 0.75 PGR (0.38) CASP1CASP7HSD17B10PGRPBRM1
SCHEMBL31674157 0.75 HSD17B1 (0.41) CASP1CASP7HSD17B10PGRPBRM1
SCHEMBL21468537 0.73 KDM4E (0.47) CASP1HSD17B10NPSR1KDM4EMEN1
SCHEMBL434862 0.72 TYMS (0.51) CASP1CASP7HSD17B10PBRM1GRM5
SCHEMBL21505155 0.72 CASP1 (0.50) CASP1CASP7HSD17B10PBRM1GRM5
SCHEMBL15180109 0.72 HSD17B10 (0.50) CASP1CASP7HSD17B10PBRM1GRM5
SCHEMBL30957305 0.72 CASP1 (0.50) CASP1CASP7HSD17B10PBRM1GRM5
SCHEMBL11980466 0.72 CASP1 (0.50) CASP1CASP7HSD17B10PBRM1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595966-B1 SYNTHESIS OF CYCLOPENTAQUINAZOLINES BTG INT LTD (GB) 2020-10-28 EP disclosed
US-8809526-B2 Synthesis of cyclopentaquinazolines ONYX PHARMACEUTICALS, INC. (US) 2014-08-19 US disclosed
US-20130211082-A1 Synthesis of Cyclopentaquinazolines ONYX PHARMACEUTICALS, INC. (US) 2013-08-15 US disclosed
EP-2595966-A2 SYNTHESIS OF CYCLOPENTAQUINAZOLINES Onyx Pharmaceuticals, Inc. (US) 2013-05-29 EP disclosed
WO-2012011939-A2 SYNTHESIS OF CYCLOPENTAQUINAZOLINES ONYX PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211082-A1 Synthesis of Cyclopentaquinazolines GLUL, QPCT, ASNS CASP1 3638/4885CASP7 3146/4885HSD17B10 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.